• PDF: Delivered by email usually within 48 UK business hours.

Meningitec (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

  • Publication Date:September 2013
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:41
  • ISBN:1591430

Meningitec (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Meningitec (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Summary

Meningococcal disease is an acute infection caused by the gram-negative bacterium Neisseria meningitidis. Its rapid onset and severity of symptoms makes prompt and effective diagnosis and treatment nearly impossible. For these reasons the meningococcal disease space is dominated by vaccines.

Meningitec (Meningococcal Serogroup C Diphtheria CRM197 Conjugate Vaccine, Adsorbed) is the brand name for Nuron Biotech's MenC conjugate vaccine sold in the EU and Australia. The vaccine was originally developed and marketed by Wyeth (now Pfizer), and Nuron Biotech acquired Meningitec in December 2012.

Scope

- Overview of Meningococcal disease, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Meningitec including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Meningitec for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Australia and Brazil.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for meningococcal vaccines
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Meningitec performance
- Obtain sales forecast for Meningitec from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)
Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 13
3.2 Symptoms 14
3.3 Prognosis 15
4 Disease Management 16
4.1 Meningococcal Immunization Policy 17
5 Competitive Assessment 20
5.1 Overview 20
5.2 Strategic Competitor Assessment 20
6 Meningitec 22
6.1 Overview 22
6.2 Efficacy 23
6.3 Safety 24
6.4 SWOT Analysis 24
6.5 Forecast 25
7 Appendix 26
7.1 Bibliography 26
7.2 Abbreviations 28
7.3 Methodology 29
7.4 Forecasting Methodology 29
7.4.1 Vaccine Coverage 30
7.4.2 Vaccine Approval vs. Routine Schedule Inclusion 30
7.4.3 Vaccines Included 31
7.4.4 Key Launch Dates 31
7.4.5 General Pricing Assumptions 32
7.4.6 Individual Vaccine Assumptions 33
7.5 Physicians and Specialists Included in this Study 34
7.6 About the Authors 38
7.6.1 Authors 38
7.6.2 Reviewers 38
7.6.3 Global Head of Healthcare 39
7.7 About GlobalData 40
7.8 Disclaimer 40



List of Tables

Table 1: Symptoms of Meningococcal Disease 15
Table 2: Meningococcal Immunization Recommendation Agencies by Country 18
Table 3: Recommended Routine Coverage and Most Administered Meningococcal Vaccines by Country in the Global Markets, 2012 19
Table 4: Leading Vaccines for Meningococcal Disease, 2012 21
Table 5: Product Profile - Meningitec 23
Table 6: Meningitec SWOT Analysis, 2012 24
Table 7: Global Sales Forecasts ($m) for Meningitec, 2012-2022 25
Table 8: Key Launch Dates 31
Table 9: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 37



List of Figures

Figure 1: Membrane Structure of N. meningitidis 12
+44 20 8816 8548

Ask a question about Meningitec (Meningococcal Vaccines) - Forecast and Market Analysis to 2022

Enter the characters you see in the picture below
Captcha